Researchers from Dana-Farber Cancer Institute Report Findings in Brain Metastasis [Neratinib and Ado-trastuzumab Emtansine for Pretreated and Untreated Human Epidermal Growth Factor Receptor 2 (Her2)-positive Breast Cancer Brain Metastases:...].

A recent study conducted by researchers at the Dana-Farber Cancer Institute in Boston, Massachusetts, focused on treatment options for human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BCBMs). The study examined the efficacy of neratinib plus T-DM1 in patients with HER2-positive BCBM, showing promising results in terms of intracranial activity and overall survival. The research concluded that neratinib-based combinations could be beneficial for patients with HER2-positive BCBM, even those who have been heavily pretreated. This study was funded by various organizations, including Puma Biotechnology, Inc., and has been peer-reviewed. [Extracted from the article]